scholarly journals Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review

Author(s):  
Congcong Liu ◽  
Jinsong Gao ◽  
Juntao Liu
Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Tetsuya Sakamoto ◽  
Yasufumi Asai ◽  
Ken Nagao ◽  
Yoshio Tahara ◽  
Takahiro Atsumi ◽  
...  

Background: In Japan, extracorporeal cardiopulmonary resuscitation (ECPR) became popular for cardiac arrest patients who resist conventional advanced life supports. Regardless of many clinical experiences, there has been no previous systematic literature review. Methods: Case series, reports and proceedings of scientific meeting about ECPR for out-of-hospital cardiac arrest written in Japanese between January 1, 1983 and July 31, 2007 were collected with Japana Centra Revuo Medicina (medical publication database in Japan) and review by experts. The outcome and characteristics of the patients were investigated, and the influence of publication bias of the case series study was also examined by the Funnel Plot method. Results: There were 951 out-of-hospital cardiac arrest patients who received ECPR in 92 reports (including 59 case series and 33 case reports) during the period. The average of age was 38.1 (4 – 88) years old and 76.1% was male. Three hundreds and eighty-one cases (40.1%) were arrests of cardiac etiology, and 212 were non-cardiac (22.3%). The cause of arrest was not described in other 37.6%. Excluding reports for only one case, weighted survival rate at discharge of 792 cases those were clearly described the outcome was 39.5±10.0%. When the relationship between the number of cases and the survival rate at discharge in each 59 case series study was shown in figure by the Funnel Plot method, the plotted data presented the reverse-funnel type that centered on the average of survival rate of all. Conclusions: The influence of publication bias of previous reports in Japan was relatively low. ECPR can greatly contribute to improve the outcome of out-of hospital cardiac arrests.


Author(s):  
Marcio Bruno Figueiredo Amaral ◽  
Samuel Macedo Costa ◽  
Vasco Oliveira de Araújo ◽  
Flavio Medeiros ◽  
Roger Lanes Silveira

2019 ◽  
Vol 6 (4) ◽  
pp. 158-164
Author(s):  
Chun‐Chi Yang ◽  
Hsing‐Tao Kuo ◽  
Ming‐Jen Sheu ◽  
Wen‐Chieh Huang ◽  
Chi‐Shu Sun ◽  
...  

2021 ◽  
Vol 16 (13) ◽  
pp. 1100-1103
Author(s):  
Luis Ortega-Paz ◽  
Salvatore Brugaletta ◽  
Josep Gomez-Lara ◽  
Juan Sanchis ◽  
José Antonio Fernández-Díaz ◽  
...  

2021 ◽  
Author(s):  
SHAOXIAN HU ◽  
MEI YU ◽  
XIAOWEI HUANG ◽  
RUI XING ◽  
YIKAI YU

Abstract Objectives: Systemic autoinflammatory disease (SAID) is a rare systemic auto-inflammatory and progressive disorders. There have been some reports with various therapies in SAID patients. The objective of this study is to describe the chareatercis of four cases of NAIDs benefiting from JAK 1/2 inhibitor baricitinib.Methods: We reported the four cases with SAID including two cases of Blau syndrome, one case of FMF and one case of FCAS3 syndrome. These four different patients were either resistant to currently available therapies or biologics were unaccessible during COVID-19 pandemic. We also conducted a systematic literature review about the current therapies of SAID.Results: Although genetically and phenotypically different, four cases of SAID that were treated with single use baricitinib 4 mg per day achieved improvement over eight weeks. We further identified 132 manuscripts providing more than 100 cases of SAID. Among these patients, 24 underwent biological treatments and 22 of them recovered. In these 132 manuscripts, 2 underwent JAK 1/3 inhibitor tofacitinib treatment and recovered fully.Conclusions: Case series study on the use of Jak inhibitor agents have yielded positive results in our study. For SAID patients baricitinib may be a better choice compared to injection biological treatments.


Sign in / Sign up

Export Citation Format

Share Document